Early study supports freezing for prostate cancer
This article was originally published in Clinica
Executive Summary
Cryoablation is an effective treatment for prostate cancer, reduces complications and costs less than either radiotherapy or surgery. Preliminary data from 310 patients show only 10% recurrence, although follow-up ranges from only three months to two years, Dr Duke Bahn of the Crittenton Hospital, Rochester, Minnesota, told the American Roentgen Ray Society's annual meeting in Washington last month. Dr Bahn says complications are infrequent and incontinence is only 1% compared with about 30% in surgery patients.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.